Hypersensitivity News and Research RSS Feed - Hypersensitivity News and Research

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.
MGH-led study confirms safety of allergy immunotherapy

MGH-led study confirms safety of allergy immunotherapy

A team of Massachusetts General Hospital investigators has found no evidence of infections related to administration of allergy immunotherapy, the common practice of injecting minimal quantities of allergens beneath the skin to reduce the allergic response. [More]
New BioMinF toothpaste ingredient helps prevent decay and treat sensitivity

New BioMinF toothpaste ingredient helps prevent decay and treat sensitivity

A new toothpaste ingredient which puts back the lost minerals from tooth enamel and helps prevent decay and treat sensitivity while you sleep is available online and from specialist dental distributors now. It is expected to be available through high street stores by the end of the year. [More]
Cinqair (reslizumab) approved for treatment of severe asthma

Cinqair (reslizumab) approved for treatment of severe asthma

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
FDA takes actions to help women, doctors better understand potential problems associated with Essure

FDA takes actions to help women, doctors better understand potential problems associated with Essure

The U.S. Food and Drug Administration announced today actions to provide important information about the risks of using Essure and to help women and their doctors be better informed of the potential complications associated with implantable forms of sterilization. [More]
Study assesses health problems related to food hypersensitivity

Study assesses health problems related to food hypersensitivity

A study by researchers at the University of Southampton and Southampton General Hospital, is the first to assess the prevalence of two different types of food hypersensitivity and the risk factors associated with them. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). [More]
Study: Many school children avoid basic foods due to perceived hypersensitivity

Study: Many school children avoid basic foods due to perceived hypersensitivity

A study on hypersensitivity to the basic foods milk, egg, fish and wheat among young school children showed that reported food hypersensitivity was eight times more common than allergies confirmed by allergy tests. This according to a new dissertation at Umeå University. [More]
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil). [More]
Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available by prescription at pharmacies across the United States. [More]
Drugs designed to curb Rac1 signaling pathway may help relieve inflammatory pain in sufferers

Drugs designed to curb Rac1 signaling pathway may help relieve inflammatory pain in sufferers

New research uncovers a cascade of reactions within nerve cells that relay sensations of pain associated with inflammation. The findings, which are published in the British Journal of Pharmacology, indicate that drugs designed to curb this pathway may help relieve inflammatory pain in sufferers. [More]
Children with sensory processing disorder have altered pathways for brain connectivity

Children with sensory processing disorder have altered pathways for brain connectivity

Researchers at UC San Francisco have found that boys and girls with sensory processing disorder (SPD) have altered pathways for brain connectivity when compared to typically developing children, and the difference predicts challenges with auditory and tactile processing. [More]
Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan. [More]
FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection. [More]
Lilly receives FDA approval for Humulin R U-500 KwikPen

Lilly receives FDA approval for Humulin R U-500 KwikPen

The U.S. Food and Drug Administration has approved Eli Lilly and Company's Humulin R U-500 KwikPen(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Advertisement
Advertisement